All In Biotech

BLA 761045 · Sandoz INC

Ziextenzo

Pegfilgrastim-Bmez · Injection · Leukocyte Growth Factor

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 4, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

400

72 Phase 3, 30 recruiting

FAERS reports

607

506 serious, 190 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 14, 2026.

ZIEXTENZO is a leukocyte growth factor indicated to • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 ) Limitations of Use ZIEXTENZO is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy ZIEXTENZO is indicated in adults and pediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies ( 14.1 )]. Limitations of Use ZIEXTENZO is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. 1.2 Patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome ZIEXTENZO is indicated to increase survival in adults and pediatric patients aged newborn and older acutely exposed to myelosuppressive doses of radiation [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14.2 )].

Mechanism: Pegfilgrastim products are colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 4, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • ZIEXTENZO · PEGFILGRASTIM-BMEZ 6MG/0.6ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pegfilgrastim" as an intervention, any sponsor and status, largest first.

All 400 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death133
  • neutropenia49
  • off label use48
  • fatigue42
  • nausea38
  • vomiting37
  • drug ineffective36
  • sepsis34
  • back pain32
  • c-reactive protein increased29
  • pyrexia29
  • candida infection28

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20198
202046
202174
2022120
2023141
2024120
202577
202621

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ziextenzo (PEGfilgrastim-Bmez)

2024 spending

$2.5M

Beneficiaries

196

556 claims

Per beneficiary

$12,767

$6,396.66 per unit

View as table
YearSpending
2020$543,666
2021$4,066,907
2022$9,307,658
2023$10,427,658
2024$2,502,372

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 308 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.